Journal article
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
Abstract
BACKGROUND: The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic hormone-refractory prostate cancer. Survival and symptom control were superior following 3-weekly docetaxel as compared with mitoxantrone. At progression, many patients were treated with the other drug. Here, we provide a retrospective report of survival and prostate-specific antigen (PSA) …
Authors
Berthold DR; Pond GR; de Wit R; Eisenberger M; Tannock IF; investigators OBOTT
Journal
Annals of Oncology, Vol. 19, No. 10, pp. 1749–1753
Publisher
Elsevier
Publication Date
October 2008
DOI
10.1093/annonc/mdn288
ISSN
0923-7534